Sarclisa (isatuximab-irfc) Approved as a Subcutaneous Injection for Multiple Myeloma by the FDA (https://www.myeloma.org/news-events/multiple-myeloma-news/subcutaneous-sarclisa-isatuximab-fda-approved-for-myeloma)